1500 IU vitamin D minimum - 10,000 IU is safe – review

Created March 2012

A 21st century evaluation of the safety of oral vitamin D

Michael J. Glade, Ph.D. thenutrition[email protected]

The Nutrition Doctor, Skokie, Illinois, USA

Nutrition. Volume 28, Issue 4 , Pages 344-356, April 2012

Received 31 March 2011; accepted 9 November 2011. PMID: 22414585

The safety of daily consumption of vitamin D was examined. A detailed literature search was conducted using the search term vitamin D; primary and secondary sources of original data and meta-analyses and systematic reviews were evaluated and summarized.

A large body of scientific evidence demonstrates that long-term daily intakes of 600 to 800 IU of vitamin D are insufficient to achieve and sustain vitamin D adequacy (serum 25-hydroxyergocalciferol + 25-hydroxycholecalciferol concentration >75 nmol/L).

Maximization of the physiologic benefits of vitamin D to

  • the musculoskeletal system,

  • the central and peripheral nervous systems,

  • the heart and central and peripheral cardiovascular systems,

  • the respiratory system,

  • the skin,

  • the eyes,

  • dentition,

  • glucoregulation,

  • immunoregulation, and

  • disease resistance

requires daily vitamin D intakes of at least 1500 IU .

Because long-term daily intakes up to and including 10 000 IU of vitamin D do not produce signs or symptoms of vitamin D toxicity and are safe for the entire general population of otherwise healthy adults, even daily vitamin D intakes of 2000 IU allow for the often-cited and excessively conservative five-fold safety factor .

In conclusion, long-term daily intakes of up to and including 10 000 IU of vitamin D maximize physiologic benefits and are safe.

[Dr. Michael Glade is an eminent nutritional specialist, educator and researcher, noted for his expert evaluation of peer reviewed evidence for the FDA in health claim evaluation.]

See also Vitamin D Life

image

References

  1. Norman AW. From vitamin D to hormone D: fundamentals ofthe vitamin D endocrine system essential for good health. AmJ Clin Nutr. 2008;88:491S–9

  2. Bischoff-Ferrari HA,Giovannucci E, Willett WC, Dietrich T,Dawson-Hughes B. Estimation of optimal serumconcentrations of 25-hydroxyvitamin D for multiple health outcomes.Am J Clin Nutr. 2006;84:18–28

  3. Holick MF.High prevalence of vitamin D inadequacy and implications forhealth. Mayo Clin Proc. 2006;81:353–373

  4. Haussler MR,Haussler CA, Bartik L, Whitfield GK, Hsieh JC,Slater S, et al. Vitamin D receptor:Molecular signaling and actions of nutritional ligands in diseaseprevention. Nutr Rev. 2008;66(suppl 2):S98–112

  5. Jurutka PW,Bartik L, Whitfield GK, Mathern DR, Barthel TK,Gurevich M, et al. Vitamin D receptor: keyroles in bone mineral pathophysiology, molecular mechanism ofaction, and novel nutritional ligands. J Bone MinerRes. 2007;22(suppl 2):V2–10

  6. Nagpal S,Na S, Rathnachalam R. Noncalcemic actions ofvitamin D receptor ligands. Endocr Rev.2005;26:662–687

  7. Bikle D.Nonclassic actions of vitamin D. J ClinEndocrinol Metab. 2009;94:26–34

  8. Holick MF.The vitamin D epidemic and its health consequences. JNutr. 2005;135:2739S–48

  9. Holick MF.The vitamin D deficiency pandemic and consequences fornonskeletal health: mechanisms of action. Mol AspectsMed. 2008;29:361–368

  10. Mathieu C,Gysemans C, Giulietti A, Bouillon R. VitaminD and diabetes. Diabetologia. 2005;48:1247–1257

  11. Williams S,Malatesta K, Norris K. Vitamin D and chronickidney disease. Ethn Dis. 2009;19(suppl 5):S5–S811

  12. Knight JA,Lesosky M, Barnett H, Raboud JM, Vieth R.Vitamin D and reduced risk of breast cancer: apopulation-based case–control study. CancerEpidemiol Biomarkers Prev. 2007;16:422–429

  13. Khazai N,Judd SE, Tangpricha V. Calcium and vitamin D:skeletal and extraskeletal health. Curr Rheumatol Rep.2008;10:110–117

  14. Instituteof Medicine. Dietary reference intakes for calcium andvitamin D. Washington, DC: National Academies Press; 2011;

  15. Yetley EA,Brulé D, Cheney MC, Davis CD, Esslinger KA,Fischer PW, et al. Dietary reference intakesfor vitamin D: justification for a review of the 1997 values. AmJ Clin Nutr. 2009;89:719–727

  16. Cranney A,Weiler HA, O’Donnell S, Puil L. Summaryof evidence-based review on vitamin D efficacy and safety inrelation to bone health. Am J Clin Nutr.2008;88:513S–9

  17. Ilahi M,Armas LA, Heaney RP. Pharmacokinetics of a single,large dose of cholecalciferol. Am J Clin Nutr.2008;87:688–691

  18. Romagnoli E,Mascia ML, Cipriani C, Fassino V, Mazzei F,D’Erasmo E, et al. Short and long-termvariations in serum calciotropic hormones after a single very largedose of ergocalciferol (vitamin D2)or cholecalciferol (vitamin D3)in the elderly. J Clin Endocrinol Metab.2008;93:3015–3020

  19. Jones G.Pharmacokinetics of vitamin D toxicity. Am JClin Nutr. 2008;88:582S–6

  20. Dawson-Hughes B,Harris SS, Dallal GE. Plasma calcidiol, season,and serum parathyroid hormone concentrations in healthy elderly menand women. Am J Clin Nutr. 1997;65:67–71

  21. Zerwekh JE.Blood biomarkers of vitamin D status. Am J ClinNutr. 2008;87:1087S–10891

  22. Wilkins CH,Sheline YI, Roe CM, Birge SJ, Morris JC. VitaminD deficiency is associated with low mood and worse cognitiveperformance in older adults. Am J Geriatr Psychiatry.2006;14:1032–1040

  23. Thacher TD,Clarke BL. Vitamin D insufficiency. MayoClin Proc. 2011;86:50–60

  24. Ong PY,Ohtake T, Brandt C, Strickland I, Boguniewicz M,Ganz T, et al. Endogenous antimicrobialpeptides and skin infections in atopic dermatitis. NEngl J Med. 2002;347:1151–1160

  25. Heaney RP,Barger-Lux MJ, Dowell MS, Chen TC, Holick MF.Calcium absorptive effects of vitamin D and its majormetabolites. J Clin Endocrinol Metab.1997;82:4111–4116

  26. Pawley N,Bischop NJ. Prenatal and infant predictors of bonehealth: the influence of vitamin D. Am J Clin Nutr.2004;80(suppl):1748S–51

  27. Holick MF.Vitamin D deficiency. N Engl J Med.2007;357:266–281

  28. Holick MF,Siris ES, Binkley N, Beard MK, Khan A,Katzer JT, et al. Prevalence of vitamin Dinadequacy among postmenopausal North American women receivingosteoporosis therapy. J Clin Endocrinol Metab.2005;90:3215–3224

  29. Wu K,Feskanich D, Fuchs CS, Willett WC, Hollis BW,Giovannucci EL. A nested case control study of plasma25-hydroxyvitamin D concentrations and risk of colorectal cancer. JNatl Cancer Inst. 2007;99:1120–1129

  30. Lips P,Hosking D, Lippuner K, Norquist JM, Wehren L,Maalouf G, et al. The prevalence of vitamin Dinadequacy amongst women with osteoporosis: an internationalepidemiological investigation. J Intern Med.2006;260:245–254

  31. Lips P.Vitamin D deficiency and secondary hyperparathyroidism inthe elderly: consequences for bone loss and fractures andtherapeutic implications. Endocr Rev.2001;22:477–501

  32. Mastaglia SR,Seijo M, Muzio D, Somoza J, Nuñez M,Oliveri B. Effect of vitamin D nutritional status onmuscle function and strength in healthy women aged over sixty-fiveyears. J Nutr Health Aging. 2011;15:349–354

  33. Visser M,Deeg DJ, Lips P. Longitudinal Aging StudyAmsterdam. Low vitamin D and high parathyroid hormone levels asdeterminants of loss of muscle strength and muscle mass(sarcopenia): the Longitudinal Aging Study Amsterdam. JClin Endocrinol Metab. 2003;88:5766–5772

  34. Wilkins CH,Birge SJ, Sheline YI, Morris JC. Vitamin Ddeficiency is associated with worse cognitive performance and lowerbone density in older African Americans. J Natl MedAssoc. 2009;101:349–354

  35. Hicks GE,Shardell M, Miller RR, Bandinelli S, Guralnik J,Cherubini A, et al. Associations betweenvitamin D status and pain in older adults: the Invecchiare inChianti study. J Am Geriatr Soc. 2008;56:785–791

  36. Bertone-Johnson ER,Powers SI, Spangler L, Brunner RL, Michael YL,Larson JC, et al. Vitamin D intake from foodsand supplements and depressive symptoms in a diverse population ofolder women. Am J Clin Nutr. 2011;94:1104–1112

  37. Michaëlsson K,Baron JA, Snellman G, Gedeborg R, Byberg L,Sundström J, et al. Plasma vitamin D andmortality in older men: a community-based prospective cohort study.Am J Clin Nutr. 2010;92:841–848

  38. Freedman DM,Looker AC, Chang SC, Graubard BI. Prospectivestudy of serum vitamin D and cancer mortality in the United States.J Natl Cancer Inst. 2007;99:1594–1602

  39. Boot AM,Krenning EP. de Muinck Keizer-Schrama SM. The relationbetween 25-hydroxyvitamin D with peak bone mineral density and bodycomposition in healthy young adults. J PediatrEndocrinol Metab. 2011;24:355–360

  40. Shardell M,Hicks GE, Miller RR, Kritchevsky S, Andersen D,Bandinelli S, et al. Association of lowvitamin D levels with the frailty syndrome in men and women. JGerontol A Biol Sci Med Sci. 2009;64:69–75

  41. Wang TJ,Pencina MJ, Booth SL, Jacques PF, Ingelsson E,Lanier K, et al. Vitamin D deficiency andrisk of cardiovascular disease. Circulation.2008;117:503–511

  42. Melamed ML,Muntner P, Michos ED, Uribarri J, Weber C,Sharma J, et al. Serum 25-hydroxyvitamin Dlevels and the prevalence of peripheral arterial disease: resultsfrom NHANES 2001 to 2004. Arterioscler Thromb VascBiol. 2008;28:1179–1185

  43. Bischoff-Ferrari HA,Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE,Theiler R, et al. Fall prevention withsupplemental and active forms of vitamin D: a meta-analysis ofrandomised controlled trials. BMJ. 2009;339:b3692

  44. Birge SJ,Haddad JG. 25-Hydroxycholecalciferol stimulation ofmuscle metabolism. J Clin Invest.1975;56:1100–1107

  45. Sharkey JR,Giuliani C, Haines PS, Branch LG, Busby-Whitehead J,Zohoori N. Summary measure of dietary musculoskeletalnutrient (calcium, vitamin D, magnesium, and phosphorus) intakes isassociated with lower-extremity physical performance in homeboundelderly men and women. Am J Clin Nutr.2003;77:847–856

  46. Bischoff-Ferrari HA,Dawson-Hughes B, Willett WC, Staehelin HB,Bazemore MG, Zee RY, et al. Effect ofvitamin D on falls: a meta-analysis. JAMA.2004;291:1999–2006

  47. Bischoff HA,Stahelin HB, Dick W, Akos R, Knecht M, Salis C,et al. Effects of vitamin D and calciumsupplementation on falls: a randomized controlled trial. JBone Miner Res. 2003;18:343–351

  48. Vieth R.Why the minimum desirable serum 25-hydroxyvitamin D levelshould be 75 nmol/L (30 ng/ml). Best Pract Res ClinEndocrinol Metab. 2011;25:681–691

  49. Hollis BW,Wagner CL, Drezner MK, Binkley NC. Circulatingvitamin D3 and 25-hydroxyvitamin D in humans: an important tool todefine adequate nutritional vitamin D status. J SteroidBiochem Mol Biol. 2007;103:631–634

  50. Trivedi DP,Doll R, Khaw KT. Effect of four monthly oralvitamin D3 (cholecalciferol) supplementation on fractures andmortality in men and women living in the community: randomiseddouble blind controlled trial. BMJ.2003;326:469–475

  51. Bischoff-Ferrari HA,Dietrich T, Orav EJ, Dawson-Hughes B. Positiveassociation between 25-hydroxy vitamin D levels and bone mineraldensity: a population-based study of younger and older adults. AmJ Med. 2004;116:634–639

  52. Chapuy MC,Pamphile R, Paris E, Kempf C, Schlichting M,Arnaud S, et al. Combined calcium and vitaminD3 supplementation in elderly women: confirmation of reversal ofsecondary hyperparathyroidism and hip fracture risk: the Decalyos IIstudy. Osteoporos Int. 2002;13:257–264

  53. Bischoff-Ferrari HA,Willett WC, Wong JB, Giovannucci E, Dietrich T,Dawson-Hughes B. Fracture prevention with vitamin Dsupplementation: a meta-analysis of randomized controlled trials.JAMA. 2005;293:2257–2264

  54. Khaw KT,Sneyd MJ, Compston J. Bone density parathyroidhormone and 25-hydroxyvitamin D concentrations in middle aged women.BMJ. 1992;305:273–277

  55. Devine A,Wilson SG, Dick IM, Prince RL. Effects ofvitamin D metabolites on intestinal calcium absorption and boneturnover in elderly women. Am J Clin Nutr.2002;75:283–288

  56. Cauley JA,Lacroix AZ, Wu L, Horwitz M, Danielson ME,Bauer DC, et al. Serum 25-hydroxyvitamin Dconcentrations and risk for hip fractures. Ann InternMed. 2008;149:242–250

  57. Melamed ML,Michos ED, Post W, Astor B. 25-HydroxyvitaminD levels and the risk of mortality in the general population. ArchIntern Med. 2008;168:1629–1637

  58. Autier P,Gandini S. Vitamin D supplementation and totalmortality: a meta-analysis of randomized controlled trials. ArchIntern Med. 2007;167:1730–1737

  59. Giovannucci E,Liu Y, Rimm EB, Hollis BW, Fuchs CS,Stampfer MJ, et al. Prospective study ofpredictors of vitamin D status and cancer incidence and mortality inmen. J Natl Cancer Inst. 2006;98:451–459

  60. Scragg R.Seasonality of cardiovascular disease mortality and thepossible protective effect of ultra-violet radiation. IntJ Epidemiol. 1981;10:337–341

  61. Judd SE,Tangpricha V. Vitamin D deficiency and risk forcardiovascular disease. Am J Med Sci.2009;338:40–44

  62. Pell JP,Cobbe SM. Seasonal variations in coronary heartdisease. QJM. 1999;92:689–696

  63. Fiscella K,Franks P, Vitamin D. race, and cardiovascularmortality: findings from a national US sample. Ann FamMed. 2010;8:11–18

  64. Kilkkinen A,Knekt P, Aro A, Rissanen H, Marniemi J,Heliovaara M, et al. Vitamin D status and therisk of cardiovascular disease death. Am J Epidemiol.2009;170:1032–1039

  65. Anderson JL,May HT, Horne BD, Bair TL, Hall NL,Carlquist JF, et al. Relation of vitamin Ddeficiency to cardiovascular risk factors, disease status, andincident events in a general healthcare population. AmJ Cardiol. 2010;106:963–968

  66. Giovannucci E,Liu Y, Hollis BW, Rimm EB. 25-HydroxyvitaminD and risk of myocardial infarction in men: a prospective study.Arch Intern Med. 2008;168:1174–1180

  67. Sun Q,Shi L, Rimm EB, Giovannucci EL, Hu FB,Manson JE, et al. Vitamin D intake and riskof cardiovascular disease in US men and women. Am JClin Nutr. 2011;94:534–542

  68. Scragg R,Jackson R, Holdaway IM, Lim T, Beaglehole R.Myocardial infarction is inversely associated with plasma25-hydroxyvitamin D3 levels: a community-based study. IntJ Epidemiol. 1990;19:559–563

  69. Kim DH,Sabour S, Sagar UN, Adams S, Whellan DJ.Prevalence of hypovitaminosis D in cardiovascular diseases(from the National Health and Nutrition Examination Survey 2001 to2004). Am J Cardiol. 2008;102:1540–1544

  70. Pilz S,Marz W, Wellnitz B, Seelhorst U,Fahrleitner-Pammer A, Dimai HP, et al. Associationof vitamin D deficiency with heart failure and sudden cardiac deathin a large cross-sectional study of patients referred for coronaryangiography. J Clin Endocrinol Metab.2008;93:3927–3935

  71. Zittermann A,Schleithoff SS, Tenderich G, Berthold HK, Korfer R,Stehle P. Low vitamin D status: A contributing factorin the pathogenesis of congestive heart failure?. J AmColl Cardiol. 2003;41:105–112

  72. Garland CF,Comstock GW, Garland FC, Helsing KJ, Shaw EK,Gorham ED. Serum 25-hydroxyvitamin D and colon cancer:eight-year prospective study. Lancet.1989;2:1176–1178

  73. Joffres MR,Reed DM, Yano K. Relationship of magnesium intakeand other dietary factors to blood pressure: the Honolulu HeartStudy. Am J Clin Nutr. 1987;45:469–475

  74. Forman JP,Giovannucci E, Holmes MD, Bischoff-Ferrari HA,Tworoger SS, Willett WC, et al. Plasma25-hydroxyvitamin D levels and risk of incident hypertension.Hypertension. 2007;49:1063–1069

  75. Judd SE,Nanes MS, Ziegler TR, Wilson PW, Tangpricha V.Optimal vitamin D status attenuates the age-associatedincrease in systolic blood pressure in white Americans: results fromthe third National Health and Nutrition Examination Survey. AmJ Clin Nutr. 2008;87:136–141

  76. Forman JP,Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin Dlevels and risk of incident hypertension among young women.Hypertension. 2008;52:828–832

  77. Hyppönen E,Boucher BJ, Berry DJ, Power C. 25-HydroxyvitaminD, IGF-1, and metabolic syndrome at 45 years of age: across-sectional study in the 1958 British Birth Cohort. Diabetes.2008;57:298–305

  78. Wang L,Manson JE, Buring JE, Lee IM, Sesso HD. Dietaryintake of dairy products, calcium, and vitamin D and the risk ofhypertension in middle-aged and older women. Hypertension.2008;51:1073–1079

  79. Pfeifer M,Begerow B, Minne HW, Nachtigall D, Hansen C.Effects of a short-term vitamin D3and calcium supplementation on blood pressure and parathyroidhormone levels in elderly women. J Clin EndocrinolMetab. 2001;86:1633–1637

  80. Schleithoff SS,Zittermann A, Tenderich G, Berthold HK, Stehle P,Koerfer R. Vitamin D supplementation improves cytokineprofiles in patients with congestive heart failure: a double-blind,randomized, placebo-controlled trial. Am J Clin Nutr.2006;83:754–759

  81. Björkman M,Sorva A, Risteli J, Tilvis R. Vitamin Dsupplementation has minor effects on parathyroid hormone and boneturnover markers in vitamin D–deficient bedridden olderpatients. Age Ageing. 2008;37:25–31

  82. Cashman KD,Hill TR, Cotter AA, Boreham CA, Dubitzky W,Murray L, et al. Low vitamin D statusadversely affects bone health parameters in adolescents. AmJ Clin Nutr. 2008;87:1039–1044

  83. Reinehr T,de Sousa G, Alexy U, Kersting M, Andler W.Vitamin D status and parathyroid hormone in obese childrenbefore and after weight loss. Eur J Endocrinol.2007;157:225–232

  84. Need AG,Horowitz M, Morris HA, Nordin BC. Vitamin Dstatus: effects on parathyroid hormone and 1, 25-dihydroxyvitamin Din postmenopausal women. Am J Clin Nutr.2000;71:1577–1581

  85. Freaney R,McBrinn Y, McKenna MJ. Secondaryhyperparathyroidism in elderly people: combined effect of renalinsufficiency and vitamin D deficiency. Am J Clin Nutr.1993;58:187–191

  86. Bogin E,Massry SG, Harary I. Effect of parathyroid hormoneon rat heart cells. J Clin Invest.1981;67:1215–1227

  87. Selvin E,Erlinger TP. Prevalence of and risk factors forperipheral arterial disease in the United States: Results from theNational Health and Nutrition Examination Survey, 1999–2000.Circulation. 2004;110:738–743

  88. AlMheid I, Patel R, Murrow J, Morris A, Rahman A,Fike L, et al. Vitamin D status is associatedwith arterial stiffness and vascular dysfunction in healthy humans.J Am Coll Cardiol. 2011;58:186–192

  89. Poole KE,Loveridge N, Barker PJ, Halsall DJ, Rose C,Reeve J, et al. Reduced vitamin D in acutestroke. Stroke. 2006;37:243–245

  90. Carrelli AL,Walker MD, Lowe H, McMahon DJ, Rundek T,Sacco RL, et al. Vitamin D deficiency isassociated with subclinical carotid atherosclerosis: the NorthernManhattan Study. Stroke. 2011;42:2240–2245

  91. Pilz S,Dobnig H, Fischer JE, Wellnitz B, Seelhorst U,Boehm BO, et al. Low vitamin D levels predictstroke in patients referred to coronary angiography. Stroke.2008;39:2611–2613

  92. Zehnder D,Bland R, Walker EA, Bradwell AR, Howie AJ,Hewison M, et al. Expression of25-hydroxyvitamin D3-1α-hydroxylasein the human kidney. J Am Soc Nephrol.1999;10:2465–2473

  93. Zehnder D,Bland R, Williams MC, McNinch RW, Howie AJ,Stewart PM, et al. Extrarenal expression of25-hydroxyvitamin D3-1-α-hydroxylase.J Clin Endocrinol Metab. 2001;86:888–894

  94. Buell JS,Dawson-Hughes B. Vitamin D and neurocognitivedysfunction: preventing “D”ecline?. MolAspects Med. 2008;29:415–422

  95. McCann JC,Ames BN. Is there convincing biological or behavioralevidence linking vitamin D deficiency to brain dysfunction?. FASEBJ. 2008;22:982–1001

  96. Dietrich T,Nunn M, Dawson-Hughes B, Bischoff-Ferrari HA.Association between serum concentrations of25-hydroxyvitamin D and gingival inflammation. Am JClin Nutr. 2005;82:575–580

  97. Munger KL,Zhang SM, O’Reilly E, Hernán MA,Olek MJ, Willett WC, et al. Vitamin Dintake and incidence of multiple sclerosis. Neurology.2004;62:60–65

  98. Munger KL,Levin LI, Hollis BW, Howard NS, Ascherio A.Serum 25-hydroxyvitamin D levels and risk of multiplesclerosis. JAMA. 2006;296:2832–2838

  99. Rauchhaus M,Doehner W, Francis DP, Davos C, Kemp M,Liebenthal C, et al. Plasma cytokineparameters and mortality in patients with chronic heart failure.Circulation. 2000;102:3060–3067

  100. Torre-Amione G,Kapadia S, Lee J, Durand JB, Bies RD, Young JB,et al. Tumor necrosis factor-α and tumornecrosis factor receptors in the failing human heart. Circulation.1996;93:704–711

  101. Ohtsuka T,Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y,et al. Effect of beta-blockers on circulatinglevels of inflammatory and anti-inflammatory cytokines in patientswith dilated cardiomyopathy. J Am Coll Cardiol.2001;37:412–417

  102. Smolders J,Thewissen M, Peelen E, Menheere P, Cohen Tervaert JW,Damoiseaux J, et al. Vitamin D status ispositively correlated with regulatory T cell function in patientswith multiple sclerosis. PLoS One. 2009;4:e6635

  103. Newmark HL,Newmark J. Vitamin D and Parkinson’s disease—ahypothesis. Mov Disord. 2007;22:461–468

  104. Evatt ML,Delong MR, Khazai N, Rosen A, Triche S,Tangpricha V. Prevalence of vitamin D insufficiency inpatients with Parkinson disease and Alzheimer disease. ArchNeurol. 2008;65:1348–1352

  105. Evatt ML,DeLong MR, Kumari M, Auinger P, McDermott MP,Tangpricha V, et al. High prevalence ofhypovitaminosis D status in patients with early Parkinson disease.Arch Neurol. 2011;68:314–319

  106. Knekt P,Kilkkinen A, Rissanen H, Marniemi J, Sääksjärvi K,Heliövaara M. Serum vitamin D and the risk ofParkinson disease. Arch Neurol. 2010;67:808–811

  107. Ward KA,Das G, Berry JL, Roberts SA, Rawer R, Adams JE,et al. Vitamin D status and muscle function inpost-menarchal adolescent girls. J Clin EndocrinolMetab. 2009;94:559–563

  108. Chin A,Paw MJ, de Jong N, Schouten EG, van Staveren WA,Kok FJ. Physical exercise or micronutrientsupplementation for the wellbeing of the frail elderly? A randomisedcontrolled trial. Br J Sports Med. 2002;36:126–131

  109. Bischoff-Ferrari HA,Orav EJ, Dawson-Hughes B. Effect ofcholecalciferol plus calcium on falling in ambulatory older men andwomen: a 3-year randomized controlled trial. ArchIntern Med. 2006;166:424–430

  110. Prince RL,Austin N, Devine A, Dick IM, Bruce D, Zhu K.Effects of ergocalciferol added to calcium on the risk offalls in elderly high-risk women. Arch Intern Med.2008;168:103–108

  111. deJong N, Chin A, Paw MJ, de Groot LC, de Graaf C,Kok FJ, et al. Functional biochemical and nutrientindices in frail elderly people are partly affected by dietarysupplements but not by exercise. J Nutr.1999;129:2028–2036

  112. Schauber J,Gallo RL. The vitamin D pathway: a new target forcontrol of the skin’s immune response?. ExpDermatol. 2008;17:633–636

  113. Schauber J,Dorschner RA, Coda AB, Büchau AS, Liu PT,Kiken D, et al. Injury enhances TLR2 functionand antimicrobial peptide expression through a vitamin D-dependentmechanism. J Clin Invest. 2007;117:803–811

  114. DiNardo A, Vitiello A, Gallo RL. Cutting edge:mast cell antimicrobial activity is mediated by expression ofcathelicidin antimicrobial peptide. J Immunol.2003;170:2274–2278

  115. Lee DY,Yamasaki K, Rudsil J, Zouboulis CC, Park GT,Yang JM, et al. Sebocytes express functionalcathelicidin antimicrobial peptides and can act to killpropionibacterium acnes. J Invest Dermatol.2008;128:1863–1866

  116. Murakami M,Ohtake T, Dorschner RA, Schittek B, Garbe C,Gallo RL. Cathelicidin anti-microbial peptideexpression in sweat, an innate defense system for the skin. JInvest Dermatol. 2002;119:1090–1095

  117. Agerberth B,Charo J, Werr J, Olsson B, Idali F, Lindbom L,et al. The human antimicrobial and chemotacticpeptides LL-37 and α-defensins are expressed by specificlymphocyte and monocyte populations. Blood.2000;96:3086–3093

  118. Braff MH,Zaiou M, Fierer J, Nizet V, Gallo RL.Keratinocyte production of cathelicidin provides directactivity against bacterial skin pathogens. InfectImmun. 2005;73:6771–6781

  119. Howell MD,Gallo RL, Boguniewicz M, Jones JF, Wong C,Streib JE, et al. Cytokine milieu of atopicdermatitis skin subverts the innate immune response to vacciniavirus. Immunity. 2006;24:341–348

  120. Howell MD,Wollenberg A, Gallo RL, Flaig M, Streib JE,Wong C, et al. Cathelicidin deficiencypredisposes to eczema herpeticum. J Allergy ClinImmunol. 2006;117:836–841

  121. Yamasaki K,Gallo RL. Antimicrobial peptides in human skin disease.Eur J Dermatol. 2008;18:11–21

  122. Schauber J,Gallo RL. Expanding the roles of antimicrobial peptidesin skin: alarming and arming keratinocytes. J InvestDermatol. 2007;127:510–512

  123. Wang TT,Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J,et al. Cutting edge: 1,25-dihydroxyvitamin D3is a direct inducer of antimicrobial peptide gene expression. JImmunol. 2004;173:2909–2912

  124. Gombart AF,Borregaard N, Koeffler HP. Human cathelicidinantimicrobial peptide (CAMP) gene is a direct target of the vitaminD receptor and is strongly up-regulated in myeloid cells by1,25-dihydroxyvitamin D3.FASEB J. 2005;19:1067–1077

  125. Schauber J,Oda Y, Büchau AS, Yun QC, Steinmeyer A,Zügel U, et al. Histone acetylation inkeratinocytes enables control of the expression of cathelicidin andCD14 by 1,25-dihydroxyvitamin D3.J Invest Dermatol. 2008;128:816–824

  126. Schauber J,Svanholm C, Termén S, Iffland K, Menzel T,Scheppach W, et al. Expression of thecathelicidin LL-37 is modulated by short chain fatty acids incolonocytes: relevance of signaling pathways. Gut.2003;52:735–741

  127. Millen AE,Tucker MA, Hartge P, Halpern A, Elder DE,Guerry D, et al. Diet and melanoma in acase–control study. Cancer Epidemiol BiomarkersPrev. 2004;13:1042–1051

  128. Vinceti M,Pellacani G, Malagoli C, Bassissi S, Sieri S,Bonvicini F, et al. A population-basedcase–control study of diet and melanoma risk in northernItaly. Public Health Nutr. 2005;8:1307–1314

  129. Hunter DJ,Colditz GA, Stampfer MJ, Rosner B, Willett WC,Speizer FE. Diet and risk of basal cell carcinoma ofthe skin in a prospective cohort of women. AnnEpidemiol. 1992;2:231–239

  130. vanDam RM, Huang Z, Giovannucci E, Rimm EB,Hunter DJ, Colditz GA, et al. Diet andbasal cell carcinoma of the skin in a prospective cohort of men. AmJ Clin Nutr. 2000;71:135–141

  131. Gandini S,Raimondi S, Gnagnarella P, Doré JF,Maisonneuve P, Testori A. Vitamin D and skincancer: a meta-analysis. Eur J Cancer.2009;45:634–641

  132. Dietrich T,Joshipura KJ, Dawson-Hughes B, Bischoff-Ferrari HA.Association between serum concentrations of25-hydroxyvitamin D3 and periodontal disease in the US population.Am J Clin Nutr. 2004;80:108–113

  133. Amano Y,Komiyama K, Makishima M. Vitamin D and periodontaldisease. J Oral Sci. 2009;51:11–20

  134. Black PN,Scragg R. Relationship between serum 25-hydroxyvitaminD and pulmonary function in the Third National Health and NutritionExamination Survey. Chest. 2005;128:3792–3798

  135. Wilk JB,Walter RE, Laramie JM, Gottlieb DJ, O’Connor GT.Framingham Heart Study genome-wide association: results forpulmonary function measures. BMC Med Genet.2007;8(suppl 1):S8

  136. Gilbert CR,Arum SM, Smith CM. Vitamin D deficiency andchronic lung disease. Can Respir J. 2009;16:75–80

  137. Smith W,Mitchell P, Leeder SR, Wang JJ. Plasmafibrinogen levels, other cardiovascular risk factors, andage-related maculopathy: the Blue Mountains Eye Study. ArchOphthalmol. 1998;116:583–587

  138. Klein R,Klein BE, Tomany SC, Cruickshanks KJ. Associationof emphysema, gout, and inflammatory markers with long-termincidence of age-related maculopathy. Arch Ophthalmol.2003;121:674–678

  139. Liu PT,Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR,et al. Toll-like receptor triggering of a vitaminD–mediated human antimicrobial response. Science.2006;311:1770–1773

  140. Parekh N,Chappell RJ, Millen AE, Albert DM, Mares JA.Association between vitamin D and age-related maculardegeneration in the Third National Health and Nutrition ExaminationSurvey, 1988 through 1994. Arch Ophthalmol.2007;125:661–669

  141. Freedman DM,Looker AC, Chang SC, Graubard BI. Prospectivestudy of serum vitamin D and cancer mortality in the United States.J Natl Cancer Inst. 2007;99:1594–1602

  142. Shin MH,Holmes MD, Hankinson SE, Wu K, Colditz GA,Willett WC. Intake of dairy products, calcium, andvitamin D and risk of breast cancer. J Natl CancerInst. 2002;94:1301–1311

  143. Frampton RJ,Suva LJ, Eisman JA, Findlay DM, Moore GE,Moseley JM, et al. Presence of1,25-dihydroxyvitamin D3receptors in established human cancer cell lines in culture. CancerRes. 1982;42:1116–1119

  144. Lointier P,Wargovich MJ, Saez S, Levin B, Wildrick DM,Boman BM. The role of vitamin D3in the proliferation of a human colon cancer cell line in vitro.Anticancer Res. 1987;7:817–821

  145. Kallay E,Pietschmann P, Toyokuni S, Bajna E, Hahn P,Mazzucco K, et al. Characterization of avitamin D receptor knockout mouse as a model of colorectalhyperproliferation and DNA damage. Carcinogenesis.2001;22:1429–1435

  146. Alvarez-Díaz S,Valle N, García JM, Peña C, Freije JM,Quesada V, et al. Cystatin D is a candidatetumor suppressor gene induced by vitamin D in human colon cancercells. J Clin Invest. 2009;119:2343–2358

  147. Holt PR,Arber N, Halmos B, Forde K, Kissileff H,McGlynn KA, et al. Colonic epithelial cellproliferation decreases with increasing levels of serum 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev.2002;11:113–119

  148. Murillo G,Matusiak D, Benya RV, Mehta RG. Chemopreventiveefficacy of 25-hydroxyvitamin D3in colon cancer. J Steroid Biochem Mol Biol.2007;103:763–767

  149. Ng K,Wolpin BM, Meyerhardt JA, Wu K, Chan AT,Hollis BW, et al. Prospective study ofpredictors of vitamin D status and survival in patients withcolorectal cancer. Br J Cancer. 2009;101:916–923

  150. Garland CF,Garland FC, Gorham ED. Can colon cancer incidenceand death rates be reduced with calcium and vitamin D?. AmJ Clin Nutr. 1991;54(suppl):193S–201

  151. Hartman TJ,Albert PS, Snyder K, Slattery ML, Caan B,Paskett E, et al. The association of calciumand vitamin D with risk of colorectal adenomas. J Nutr.2005;135:252–259

  152. Gorham ED,Garland CF, Garland FC, Grant WB, Mohr SB,Lipkin M, et al. Optimal vitamin D status forcolorectal cancer prevention: a quantitative meta analysis. AmJ Prev Med. 2007;32:210–216

  153. Grau MV,Baron JA, Sandler RS, Haile RW, Beach ML,Church TR, et al. Vitamin D, calciumsupplementation, and colorectal adenomas: results of a randomizedtrial. J Natl Cancer Inst. 2003;95:1765–1771

  154. Feskanich D,Ma J, Fuchs CS, Kirkner GJ, Hankinson SE,Hollis BW, et al. Plasma vitamin Dmetabolites and risk of colorectal cancer in women. CancerEpidemiol Biomarkers Prev. 2004;13:1502–1508

  155. Platz EA,Hankinson SE, Hollis BW, Colditz GA, Hunter DJ,Speizer FE, et al. Plasma 1,25-dihydroxy- and25-hydroxyvitamin D and adenomatous polyps of the distal colorectum.Cancer Epidemiol Biomarkers Prev. 2000;9:1059–1065

  156. Slattery ML,Neuhausen SL, Hoffman M, Caan B, Curtin K,Ma KN, et al. Dietary calcium, vitamin D, VDRgenotypes and colorectal cancer. Int J Cancer.2004;111:750–756

  157. Wei MY,Garland CF, Gorham ED, Mohr SB, Giovannucci E.Vitamin D and prevention of colorectal adenoma: ameta-analysis. Cancer Epidemiol Biomarkers Prev.2008;17:2958–2969

  158. Lee JE,Li H, Chan AT, Hollis BW, Lee IM, Stampfer MJ,et al. Circulating levels of vitamin D and colonand rectal cancer: the Physicians’ Health Study and ameta-analysis of prospective studies. Cancer Prev Res.2011;4:735–743

  159. Ma Y,Zhang P, Wang F, Yang J, Liu Z, Qin H.Association between vitamin D and risk of colorectal cancer:a systematic review of prospective studies. J ClinOncol. 2011;29:3775–3782

  160. Peters U,McGlynn KA, Chatterjee N, Gunter E, Garcia-Closas M,Rothman N, et al. Vitamin D, calcium, andvitamin D receptor polymorphism in colorectal adenomas. CancerEpidemiol Biomarkers Prev. 2001;10:1267–1274

  161. Barreto AM,Schwartz GG, Woodruff R, Cramer SD. 25-HydroxyvitaminD3, the prohormone of1,25-dihydroxyvitamin D3,inhibits the proliferation of primary prostatic epithelial cells.Cancer Epidemiol Biomarkers Prev. 2000;9:265–270

  162. Schwartz GG,Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF.Human prostate cells synthesize 1,25-dihydroxyvitamin D3from 25-hydroxyvitamin D3.Cancer Epidemiol Biomarkers Prev. 1998;7:391–395

  163. Peehl DM,Skowronski RJ, Leung GK, Wong ST, Stamey TA,Feldman D. Antiproliferative effects of1,25-dihydroxyvitamin D3on primary cultures of human prostatic cells. CancerRes. 1994;54:805–810

  164. Li H,Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM,Hunter D, et al. A prospective study ofplasma vitamin D metabolites, vitamin D receptor polymorphisms, andprostate cancer. PLoS Med. 2007;4:e103

  165. Tuohimaa P,Tenkanen L, Ahonen M, Lumme S, Jellum E,Hallmans G, et al. Both high and low levelsof blood vitamin D are associated with a higher prostate cancerrisk: a longitudinal, nested case–control study in the Nordiccountries. Int J Cancer. 2004;108:104–108

  166. Tuohimaa P,Tenkanen L, Syvälä H, Lumme S, Hakulinen T,Dillner J, et al. Interaction of factorsrelated to the metabolic syndrome and vitamin D on risk of prostatecancer. Cancer Epidemiol Biomarkers Prev.2007;16:302–307

  167. Kristal AR,Arnold KB, Schenk JM, Neuhouser ML, Goodman P,Penson DF, et al. Dietary patterns,supplement use, and the risk of symptomatic benign prostatichyperplasia: results from the Prostate Cancer Prevention Trial. AmJ Epidemiol. 2008;167:925–934

  168. Tretli S,Hernes E, Berg JP, Hestvik UE, Robsahm TE.Association between serum 25(OH)D and death from prostatecancer. Br J Cancer. 2009;100:450–454

  169. Fang F,Kasperzyk JL, Shui I, Hendrickson W, Hollis BW,Fall K, et al. Prediagnostic plasma vitamin Dmetabolites and mortality among patients with prostate cancer. PLoSOne. 2011;6:e18625

  170. Albanes D,Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J,et al. Serum 25-hydroxyvitamin D and prostatecancer risk in a large nested case–control study. CancerEpidemiol Biomarkers Prev. 2011;20:1850–1860

  171. Ahn J,Albanes D, Berndt SI, Peters U, Chatterjee N,Freedman ND, et al. Vitamin D–relatedgenes, serum vitamin D concentrations and prostate cancer risk.Carcinogenesis. 2009;30:769–776

  172. Torkko KC,van Bokhoven A, Mai P, Beuten J, Balic I,Byers TE, et al. VDR and SRD5A2 polymorphismscombine to increase risk for prostate cancer in both non-HispanicWhite and Hispanic White men. Clin Cancer Res.2008;14:3223–3229

  173. Holick CN,Stanford JL, Kwon EM, Ostrander EA, Nejentsev S,Peters U. Comprehensive association analysis of thevitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostatecancer. Cancer Epidemiol Biomarkers Prev.2007;16:1990–1999

  174. Cicek MS,Liu X, Schumacher FR, Casey G, Witte JS. VitaminD receptor genotypes/haplotypes and prostate cancer risk. CancerEpidemiol Biomarkers Prev. 2006;15:2549–2552

  175. Tayeb MT,Clark C, Haites NE, Sharp L, Murray GI,McLeod HL. CYP3A4 and VDR gene polymorphisms and therisk of prostate cancer in men with benign prostate hyperplasia. BrJ Cancer. 2003;88:928–932

  176. Yin M,Wei S, Wei Q. Vitamin D receptor geneticpolymorphisms and prostate cancer risk: a meta-analysis of 36published studies. Int J Clin Exp Med.2009;2:159–175

  177. Kakarala RR,Chandana SR, Harris SS, Kocharla LP, Dvorin E.Prevalence of vitamin D deficiency in uninsured women. JGen Intern Med. 2007;22:1180–1183

  178. Nesby-O’Dell S,Scanlon KS, Cogswell ME, Gillespie C, Hollis BW,Looker AC, et al. Hypovitaminosis Dprevalence and determinants among African American and white womenof reproductive age: Third National Health and Nutrition ExaminationSurvey, 1988–1994. Am J Clin Nutr.2002;76:187–192

  179. Semba RD,Garrett E, Johnson BA, Guralnik JM, Fried LP.Vitamin D deficiency among older women with and withoutdisability. Am J Clin Nutr. 2000;72:1529–1534

  180. Lappe JM,Davies KM, Travers-Gustafson D, Heaney RP. VitaminD status in a rural postmenopausal female population. JAm Coll Nutr. 2006;25:395–402

  181. Wang-Gillam A,Miles DA, Hutchins LF. Evaluation of vitamin Ddeficiency in breast cancer patients on bisphosphonates. Oncologist.2008;13:821–827

  182. McCullough ML,Robertson AS, Rodriguez C, Jacobs EJ, Chao A,Carolyn J, et al. Calcium, vitamin D, dairyproducts, and risk of colorectal cancer in the cancer preventionstudy II nutrition cohort (United States). CancerCauses Control. 2003;14:1–12

  183. Orwoll E,Nielson CM, Marshall LM, Lambert L, Holton KF,Hoffman AR, et al. Vitamin D deficiency inolder men. J Clin Endocrinol Metab.2009;94:1214–1222

  184. Kumari M,Judd SE, Tangpricha V. Vitamin D status in UnitedStates war veterans. Endocr Pract. 2008;14:127–128

  185. Hirani V,Primatesta P. Vitamin D concentrations among peopleaged 65 years and over living in private households and institutionsin England: population survey. Age Ageing.2005;34:485–491

  186. Ginde AA,Liu MC, Camargo CA. Demographic differences andtrends of vitamin D insufficiency in the US population, 1988–2004.Arch Intern Med. 2009;169:626–632

  187. Looker AC,Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF,Yetley EA. Serum 25-hydroxyvitamin D status of the USpopulation: 1988–1994 compared with 2000–2004. AmJ Clin Nutr. 2008;88:1519–1527

  188. Renzaho AM,Halliday JA, Nowson C, Vitamin D. obesity,and obesity-related chronic disease among ethnic minorities: asystematic review. Nutrition. 2011;27:868–879

  189. Barger-Lux MJ,Heaney RP, Dowell S, Chen TC, Holick MF. VitaminD and its major metabolites: Serum levels after graded oral dosingin healthy men. Osteoporos Int. 1998;8:222–230

  190. Jacobs ET,Alberts DS, Foote JA, Green SB, Hollis BW, Yu Z,et al. Vitamin D insufficiency in southernArizona. Am J Clin Nutr. 2008;87:608–613

  191. Pepper KJ,Judd SE, Nanes MS, Tangpricha V. Evaluationof vitamin D repletion regimens to correct vitamin D status inadults. Endocr Pract. 2009;15:95–103

  192. Harris SS,Dawson-Hughes B. Plasma vitamin D and 25OHD responsesof young and old men to supplementation with vitamin D3.J Am Coll Nutr. 2002;21:357–362

  193. Gertner JM,Domenech M. 25-Hydroxyvitamin D levels in patientstreated with high-dosage ergo- and cholecalciferol. JClin Pathol. 1977;30:144–150

  194. Cashman KD,Wallace JM, Horigan G, Hill TR, Barnes MS,Lucey AJ, et al. Estimation of the dietaryrequirement for vitamin D in free-living adults >=64 y of age. AmJ Clin Nutr. 2009;89:1366–1374

  195. Cashman KD,Hill TR, Lucey AJ, Taylor N, Seamans KM,Muldowney S, et al. Estimation of the dietaryrequirement for vitamin D in healthy adults. Am J ClinNutr. 2008;88:1535–1542

  196. Hollis BW,Johnson D, Hulsey TC, Ebeling M, Wagner CL.Vitamin D supplementation during pregnancy: double blind,randomized clinical trial of safety and effectiveness. JBone Miner Res. 2011;26:2341–2357

  197. Heaney RP,Davies KM, Chen TC, Holick MF, Barger-Lux MJ.Human serum 25-hydroxycholecalciferol response to extendedoral dosing with cholecalciferol. Am J Clin Nutr.2003;77:204–210

  198. Hathcock JN,Shao A, Vieth R, Heaney R. Risk assessmentfor vitamin D. Am J Clin Nutr. 2007;85:6–18

  199. Pettifor JM,Bikle DD, Cavaleros M, Zachen D, Kamdar MC,Ross FP. Serum levels of free 1,25-dihydroxyvitamin Din vitamin D toxicity. Ann Intern Med.1995;122:511–513

  200. Koutkia P,Chen TC, Holick MF. Vitamin D intoxicationassociated with an over-the-counter supplement. N EnglJ Med. 2001;345:66–67

  201. Kimball S,Vieth R. Self-prescribed high-dose vitamin D3:effects on biochemical parameters in two men. Ann ClinBiochem. 2008;45:106–110

  202. Hollis BW.Circulating 25-hydroxyvitamin D levels indicative of vitaminD sufficiency: Implications for establishing a new effective dietaryintake recommendation for vitamin D. J Nutr.2005;135:317–322

  203. Mason RS,Lissner D, Grunstein HS, Posen S. Asimplified assay for dihydroxylated vitamin D metabolites in humanserum: application to hyper- and hypovitaminosis D. ClinChem. 1980;26:444–450

  204. Bischoff-Ferrari HA,Dietrich T, Orav EJ, Hu FB, Zhang Y, Karlson EW,et al. Higher 25-hydroxyvitamin D concentrationsare associated with better lower-extremity function in both activeand inactive persons aged > or =60 y. Am J ClinNutr. 2004;80:752–758

  205. Barger-Lux MJ,Heaney RP. Effects of above average summer sun exposureon serum 25-hydroxyvitamin D and calcium absorption. JClin Endocrinol Metab. 2002;87:4952–4956

  206. Vieth R.Vitamin D supplementation, 25-hydroxyvitamin Dconcentrations, and safety. Am J Clin Nutr.1999;69:842–856

  207. Jorde R,Sneve M, Torjesen PA, Figenschau Y, Hansen JB,Grimnes G. No significant effect on bone mineraldensity by high doses of vitamin D3given to overweight subjects for one year. Nutr J.2010;9:1

  208. Sneve M,Figenschau Y, Jorde R. Supplementation withcholecalciferol does not result in weight reduction in overweightand obese subjects. Eur J Endocrinol.2008;159:675–684

  209. Amir E,Simmons CE, Freedman OC, Dranitsaris G, Cole DE,Vieth R, et al. A phase 2 trial exploring theeffects of high-dose (10,000 IU/day) vitamin D(3) in breast cancerpatients with bone metastases. Cancer.2010;116:284–291

  210. Smolders J,Peelen E, Thewissen M, Cohen Tervaert JW, Menheere P,Hupperts R, et al. Safety and T cellmodulating effects of high dose vitamin D3 supplementation inmultiple sclerosis. PLoS One. 2010;5:e15235

  211. Stern PH,Taylor AB, Bell NH, Epstein S. Demonstrationthat circulating 1α,25-dihydroxyvitamin D is loosely regulatedin normal children. J Clin Invest.1981;68:1374–1377

  212. Stamp TC.Factors in human vitamin D nutrition and in the productionand cure of classical rickets. Proc Nutr Soc.1975;34:119–130

  213. Armas LA,Hollis BW, Heaney RP. Vitamin D2 is much lesseffective than vitamin D3 in humans. J Clin EndocrinolMetab. 2004;89:5387–5391

  214. Khaw KT,Scragg R, Murphy S. Single-dose cholecalciferolsuppresses the winter increase in parathyroid hormone concentrationsin healthy older men and women: a randomized trial. AmJ Clin Nutr. 1994;59:1040–1044

  215. El-HajjFuleihan G, Nabulsi M, Tamim H, Maalouf J,Salamoun M, Khalife H, et al. Effect ofvitamin D replacement on musculoskeletal parameters in schoolchildren: a randomized controlled trial. J ClinEndocrinol Metab. 2006;91:405–412

  216. Maalouf J,Nabulsi M, Vieth R, Kimball S, El-Rassi R,Mahfoud Z, et al. Short- and long-term safetyof weekly high-dose vitamin D3supplementation in school children. J Clin EndocrinolMetab. 2008;93:2693–2701

  217. Arpadi SM,McMahon D, Abrams EJ, Bamji M, Purswani M,Engelson ES, et al. Effect of bimonthlysupplementation with oral cholecalciferol on serum 25-hydroxyvitaminD concentrations in HIV-infected children and adolescents.Pediatrics. 2009;123:e121–e126

  218. Sanders KM,Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA,Young D, et al. Annual high-dose oral vitaminD and falls and fractures in older women: a randomized controlledtrial. JAMA. 2010;303:1815–1822

  219. Kimball SM,Ursell MR, O’Connor P, Vieth R. Safetyof vitamin D3 in adultswith multiple sclerosis. Am J Clin Nutr.2007;86:645–651

  220. Hathcock JN,Shao A. Expanded approach to tolerable upper intakeguidelines for nutrients and bioactive substances. JNutr. 2008;138:1992S–5

  221. FAO/WHO. A model forestablishing upper levels of intake for nutrients and relatedsubstances. Report of a joint FAO/WHO technical workshop on nutrientrisk assessment. Geneva: World Health Organization; 2005;


Tags: How much